Company intelligence / Profile preview

Maxia Pharmaceuticals

San Diego, California, United Statesmaximapharma.com ↗

Ownership: Private
Employees: ~28
Development stage: Other

Overview

Maxia’s most advanced internal program was a novel insulin sensitizer for Type II diabetes in late preclinical testing. Other programs targeting kinases and protein phosphatase inhibitors were at early discovery or preclinical stages. A topical treatment for cervical dysplasia had completed Phase II but reverted to Galderma upon acquisition. No products reached commercial stage under the Maxia name.

Therapeutic areas: OncologyEndocrinologyCardiovascularImmunology
Modalities: Small molecules
Industry: Biotech

Partnerships

Johnson & Johnson (for some diabetes compounds)Galderma Research Inc. (licensed compound library; non-core asset returned on acquisition completion)

Beyond the preview

Go deeper on Maxia Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Maxia Pharmaceuticals.

Explore the full profile